By Bill Fisher | October 21st, 2020
For people who were previously in the trial, they will be re-invited to join a two year study and re-grouped based on how their disease has progressed, what dosage they had took and if they did take the placebo. They will not be excluded or barred from rejoining the open-labels study. For people who weren’t apart of this study originally we are thinking that the FDA will give fast-track review of the aducanumab submissions. This will mean that the wait will be around 7 months for trial placements.